<DOC>
	<DOCNO>NCT00712829</DOCNO>
	<brief_summary>This single blind , randomize , cross-over design . Up 12 patient randomly administer single 10.0 mCi dose 123I-MIP-1072 123I-MIP-1095 ( study drug ) . The second ( alternate ) study drug administer approximately 14 day first . A final follow-up visit occur approximately 2 week injection alternate study drug .</brief_summary>
	<brief_title>Study Evaluate Safety , Pharmacokinetics , Tissue Distribution , Metabolism Dosimetry Two Prostate Cancer Imaging Agents</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Have prior histological diagnosis prostate cancer . Have evidence recurrent metastatic disease demonstrate abnormal bone scan , CT scan MRI plus : 1 . PSA &gt; 1.0 patient post prostatectomy post ablative radiotherapy , 2 . PSA &gt; 20 intact prostate Have platelet count &gt; 50,000/mm3 Have neutrophil count &gt; 1,000/mm3 Provide write informed consent willing comply protocol requirement Greater equal 18 year age Can hormonal therapy dose stable &gt; 90 day Karnofsky performance status &lt; 60 Inadequate venous access ( two antecubital equivalent venous access site require study drug injection PK blood sampling , respectively ) Patient receive permanent prostate brachytherapy implant within last 3 month ( Pd103 implant ) 12 month ( I125 implant ) . Patient receive external beam therapy chemotherapy within last 30 day Administered radioisotope within 5 physical half live prior study enrollment Serum creatinine &gt; 3.5 mg/dL Total bilirubin &gt; 2.5 time upper limit normal Liver transaminases great 5x upper limit normal Received investigational compound and/or medical device part investigational study within past 30 day enrollment study Have medical condition circumstance , opinion Investigator , would significantly decrease chance obtain reliable data , achieve study objective , complete study and/or post dose followup examination Is determined Investigator patient clinically unsuitable study Have malignancy within 5 year basal squamous cell carcinoma skin .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Imaging</keyword>
</DOC>